MC 16
Alternative Names: MC-16Latest Information Update: 28 Feb 2026
At a glance
- Originator MitoChem Therapeutics
- Class Carbamates; Eye disorder therapies; Neuroprotectants; Small molecules
- Mechanism of Action Mitochondrial oxidative phosphorylation modulators
-
Orphan Drug Status
Yes - Retinitis pigmentosa
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis
- No development reported Retinitis pigmentosa
- Discontinued Dry age-related macular degeneration; Glaucoma
Most Recent Events
- 28 Feb 2026 No recent reports of development identified for preclinical development in Retinitis-pigmentosa in USA (Ophthalmic, Drops)
- 06 Feb 2026 Discontinued - Preclinical for Dry age-related macular degeneration in USA (Ophthalmic) (MitoChem Therapeutics pipeline, February 2026)
- 06 Feb 2026 Discontinued - Preclinical for Glaucoma in USA (Ophthalmic) (MitoChem Therapeutics pipeline, February 2026)